Results 181 to 190 of about 159,852 (315)

Integrated Clinical and Proteomic Profiling of CD19 Chimeric Antigen Receptor T Cell Therapy in Progressive Systemic Sclerosis

open access: yesArthritis &Rheumatology, EarlyView.
Objective To characterize the clinical, immunologic, and proteomic changes associated with CD19 chimeric antigen receptor T cell therapy in patients with progressive systemic sclerosis (SSc). Methods Patients with progressive SSc received CD19 chimeric antigen receptor (CAR)‐T cell therapy and were observed longitudinally for safety, clinical efficacy,
Chenhan Jia   +16 more
wiley   +1 more source

Expert Perspectives: Defining and Managing Progressive Pulmonary Fibrosis in Systemic Sclerosis

open access: yesArthritis &Rheumatology, EarlyView.
Systemic sclerosis–associated interstitial lung disease (SSc‐ILD) is one of the leading causes of morbidity and mortality in SSc, affecting up to three‐quarters of patients. The disease course is highly heterogeneous, ranging from indolent, nonprogressive forms to rapidly progressive pulmonary fibrosis (PPF).
Devis Benfaremo   +7 more
wiley   +1 more source

Antigen Microarray Reveals Broad and Subclinical Autoimmunity in Patients with Inborn Errors of Immunity. [PDF]

open access: yesJ Clin Immunol
Zhang W   +10 more
europepmc   +1 more source

Homocitrullinated Peptides Drive Pro‐Inflammatory T Cell Responses in a Humanized Mouse Model of Rheumatoid Arthritis

open access: yesArthritis &Rheumatology, EarlyView.
Objective Anti‐homocitrullinated protein/peptide antibodies are specific to rheumatoid arthritis (RA) and predictive of worse prognosis, suggesting a pathogenic role for autoreactivity to homocitrullinated peptides (HomoCitP). However, T cell responses to HomoCitP remain largely unexplored.
Sofya Ulanova   +6 more
wiley   +1 more source

Non-Conventional and Emerging Autoantibodies in Sjögren’s Disease

open access: yesJournal of Inflammation Research
Adrian YS Lee1,2 1Department of Clinical Immunology & Allergy, Westmead Hospital & ICPMR, Sydney, NSW, Australia; 2Centre for Immunology & Allergy Research, Westmead Institute for Medical Research, The University of Sydney, Sydney, NSW ...
Lee AYS
doaj  

Absence of autoantibodies linked to cancer and autoimmune disorders 26 weeks after BNT162b2 boosting in CoronaVac- primed individuals. [PDF]

open access: yesHum Vaccin Immunother
Mat Yassim AS   +6 more
europepmc   +1 more source

From Interferon Signature to the Clinical Landscape: Type I Interferonopathies

open access: yesArthritis &Rheumatology, Accepted Article.
Background Type I interferonopathies are heterogeneous diseases driven by dysregulated IFN‐I signaling. Diagnosis is challenging due to clinical/molecular variability and the need for IFN‐I quantification. Objective To characterize the clinical, immunological, genetic, molecular profiles of patients with suspected enhanced IFN‐I signaling, and assess ...
Ismail Yaz   +13 more
wiley   +1 more source

The role of IgM anti‐acetylated protein antibodies and B cells in the origin of anti‐modified protein autoimmunity in rheumatoid arthritis

open access: yesArthritis &Rheumatology, Accepted Article.
Objective Rheumatoid arthritis (RA) is characterized by anti‐modified protein antibodies (AMPAs), including anti‐citrullinated (ACPA), anti‐carbamylated (anti‐CarP), and anti‐acetylated (AAPA) protein antibodies. In contrast to other AMPAs, AAPA IgM is found in healthy individuals, raising questions about its role in early immune responses.
Aegli Athanasiadou   +10 more
wiley   +1 more source

Cross-sectional Study of Dermatitis Herpetiformis with Focus on Neurological Comorbidities. [PDF]

open access: yesActa Derm Venereol
Malkovics T   +5 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy